Patent · US Active

Engineered retrons and methods of use

US12054739B2 · kind B2 · utility

0Cited by

9References

30Claims

0Family size

Assignee

ReNAgade Therapeutics Management, Inc. · US

Inventors

Alim Ladha · Cambridge, US
Vladimir Presnyak · Manchester, US
Inna Shcherbakova · Holliston, US
Brian Goodman · Brookline, US
Mario Rodriguez Mestre · Cambridge, US
Devin Scott Quinlan · Cambridge, US
Muthusamy Jayaraman · Cambridge, US
Stephen Scully · Fort Lauderdale, US

Key dates

Filing date	Sep 22, 2023
Grant date	Aug 6, 2024
Priority date	—
Expiry date	Sep 22, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/80
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Disclosed are engineered retrons and methods of use such as to modify the genome of a host (e.g., mammalian) cell by delivering the engineered retron or the encoded ncRNA in vitro or in vivo to the host (e.g., mammalian) cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.